Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif.
| Revenue (Most Recent Fiscal Year) | $201.49M |
| Net Income (Most Recent Fiscal Year) | $-66.54M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.87 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.69 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -14.81% |
| Net Margin (Trailing 12 Months) | -33.02% |
| Return on Equity (Trailing 12 Months) | -7.70% |
| Return on Assets (Trailing 12 Months) | -5.89% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.04 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.42 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.99 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.67 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.04 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.26 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.51 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 127.86M |
| Free Float | 114.66M |
| Market Capitalization | $579.23M |
| Average Volume (Last 20 Days) | 0.77M |
| Beta (Past 60 Months) | 1.28 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.33% |
| Percentage Held By Institutions (Latest 13F Reports) | 69.46% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |